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Neuroblastoma (NB) is the most common extracranial tumor in children and accounts for around 15% of all paediatric oncology
deaths. The treatment of NB includes surgery, chemotherapy, and radiotherapy. Unfortunately, most children with NB present
with advanced disease, and more than 60% of patients with high-risk features will have a poor prognosis despite intensive therapy.
Agonistsofthenuclear receptor peroxisomeproliferator-activatedreceptor γ (PPARγ)havebeen showntohavepleiotropiceﬀects,
including antineoplastic eﬀects. The studies that addressed the role and the possible mechanism(s) of action of PPARγ in NB cells
are reviewed.
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1. INTRODUCTION
Neuroblastoma (NB), the most common extracranial solid
tumor in children, accounts for more than 7% of malig-
nancies in patients younger than 15 years and around 15%
of all paediatric oncology deaths [1]. The disease has a
heterogeneous clinical presentation and course [2]. First of
all, NB is a disease of the sympaticoadrenal lineage of the
neural crest, and therefore tumors can develop anywhere
in the sympathetic nervous system. The majority of NB is
developed within the abdomen and at least 50% of these
tumors arise in the adrenal medulla [2]. Other frequent
localizations include the neck, chest, and pelvis [3]. The
clinical presentation of the disease may be also highly
variable and depends on the site of the primary tumor as
well as on the presence or absence of metastatic disease
(mostly haematogeneous dissemination to cortical bone,
bone marrow, liver, and noncontiguous lymph nodes) or
paraneoplastic syndromes. The diagnosis of NB is based
on histopathological assessment of tumor tissue or on the
detection of cancer cells in a bone marrow aspirate/biopsy,
together with the presence of increased levels of urinary cat-
echolamines [2]. Imaging studies for the localization of the
disease include computed tomography, magnetic resonance,
99mTc-diphosphonate, or metaiodobenzylguanidine (using
123I) scintigraphy for the detection of bone metastases.
The treatment of NB includes surgery, chemotherapy
(i.e., cisplatin, etoposide, doxorubicin, cyclophosphamide,
vincristine) [4], and radiotheraphy. Unfortunately, although
substantial improvement in outcome of certain subsets of
patients has been observed during the past few decades [2],
most children with NB present with advanced disease and
more than 60% of patients with high-risk features will have
a poor prognosis despite intensive therapy [5, 6]. Thus,
research eﬀorts to understand the biological basis of NB and
to identify new and more eﬀective therapies are essential to
improve the outcome for these children. In the last years
an expanding number of new agents have been developed
for use in high-risk patients aﬀected by recurrent disease.
Cytotoxic agents, such as the topoisomerase 1 inhibitors
topotecan and irinotecan, have an acceptable toxicity proﬁle
and are eﬀectively used in early relapsing NB [7–10].
The delivery of radioactive molecules that are selectively
concentrated in NB cells, such as metaiodobenzylguani-
dine,somatostatinanalogues,anti-GD2 (adisialoganglioside)
antibodies, has been used in clinical trials [11–22]. GD2-
targeted therapies using monoclonal antibodies are under
investigation in phase III trials [19, 23, 24], and other
immunotherapeutic strategies (i.e., vaccination or cellular
immunotherapy using engineered cytolityc T lymphocytes)
are currently investigated [25, 26]. Similarly, angiogenesis
[27–33] and tyrosine kinase [34–38] inhibitors appear as an2 PPAR Research
attractive therapeutic option and clinical trials are ongoing.
Retinoids have been shown to interfere with cell growth and
to induce apoptosis in NB cells [39, 40] and preliminary
clinical trials with retinoids in NB resulted in improved
event-free survival in high-risk patients, with limited toxic
eﬀects [41, 42]. Thiazolidinediones (TZDs) are a class of
molecules that activate the nuclear receptor peroxisome
proliferator-activated receptor γ (PPARγ)[ 43]a n dp r o m o t e
association with the 9-cis retinoic X receptor (RXR) to form
functional heterodimers that recognize its cognate DNA
response element within target genes [44, 45]. TZDs have
been shown to have antineoplastic eﬀects, as extensively
discussed in this issue of the journal, in agreement with
the demonstration that PPARγ/RXR signalling exerts an
important role in inhibiting cell proliferation and/or in
inducing apoptosis [46]. It has been also shown that PPARγ
and RXR ligands may have a synergistic eﬀect in inducing
cell diﬀerentiation [47, 48] and in inhibiting cell growth in
diﬀerent tumors, such as colon, lung, and breast cancer [49–
51]. There is evidence that also PPARα and PPARβ ligands
may play a role in counteracting tumoral cell growth and in
promotingcelldiﬀerentiation,includingneuroblastomacells
[52, 53]. However, most of the reports covering this issue,
that have been published in the literature so far, deal with
PPARγ agonists. Therefore, the role of PPARγ ligands as a
possible therapeutic option in NB is reviewed and discussed
here.
2. PPARγ AND PPARγ AGONISTS
IN NEUROBLASTOMA
The ﬁrst demonstration that PPARγ is expressed in NB
cells was provided by Han et al. in 2001 [54]. Using RT-
PCR the authors showed that LA-N-5 NB cells express also
PPARβ,b u tn o tP P A R α. Similarly, in sections from human
primary NB immunostaining for PPARγ was detected in
the nucleus and occasionally in the cytoplasm of cells,
particularly in those showing ganglionic diﬀerentiation.
Sato et al. [55] addressed the possibility that the amount
of expression of PPARγ in NB might be correlated to
patients’ outcome. To this purpose, the level of mRNA
was measured by semiquantitative RT-PCR in NB samples
from 17 patients under the age of one year. In this subset
of patients, spontaneous diﬀerentiation and regression are
often observed [56], and some investigators suggested to
observe these patients without surgery until there is an
increase of vanilmandelic acid (VMA) or tumoral growth
occurs[57,58].PPARγ mRNAwaspresentin12samples.No
diﬀerence between the expression of PPARγ and histology,
age,staging,DNAploidywasobserved,yetacorrelationwith
the change in urinary VMA was found. In fact, in samples
resected from patients, who showed a reduction of VMA in
the period of time preceding surgery (2–7 months), higher
PPARγ expression was detected compared to those patients
in which VMA increased. The authors hypothesized that
PPARγ mightplayaroleinthedecreaseofVMAandhencein
the regression of early-onset NB. Thereafter, several studies
addressed the potential role of endogenous or synthetic
PPARγ ligands in counteracting NB cell growth.
5-Deoxy-Δ12,14-prostaglandin J2 (15-deoxy-PGJ2)i sa
naturally occurring downstream metabolite of PGD2, that
is produced by degradationof PGD2 [59]. In contrast to
classic prostaglandins, which act after binding to cell surface
G-protein coupled receptors(GPCRs), 15-deoxy-PGJ2 is a
high-aﬃnity endogenous ligand of PPARγ.Ap r o - a p o p t o t i c
eﬀect of 15-deoxy-PGJ2 in SH-SY5Y NB cells, that was
reverted by the caspase inhibitor Z-VAD, was reported by
Rohn et al. [60]. A subsequent study conﬁrmed that 15-
deoxy-PGJ2 was able to inhibit cell growth and to induce
apoptosis via the activation of ERK2 in two additional NB
cell lines (i.e., SK-N-SH and SK-N-MC). An increase of the
expression of the pro-apoptotic proteins caspase-3, caspase-
9, and Bax, together with the decrease of the anti-apoptotic
protein Bcl-2, was also observed [61]. The PPARγ antagonist
GW9662revertedtheeﬀectsof15-deoxy-PGJ2,includingthe
activation of ERK2. The authors concluded that 15-deoxy-
PGJ2 induced apoptosis in a PPARγ-dependent manner
through the activation of ERK pathway. Another study
showed that the mechanism by which 15-deoxy-PGJ2 arrests
cell growth may vary depending on the content of lipids in
the culture medium [62]. In particular, the delipidation of
fetal calf serum, which removes known serum lipid mitogens
including lysophosphatidic acid [63] and sphingosine 1-
phosphate [64], potentiated the degree of 15-deoxy-PGJ2-
induced growth inhibition via PPARγ-dependent apoptosis
in the NB cell line IMR-32. Conversely, growth inhibition
in the presence of complete medium occurred through
programmed cell death typeII (autophagy).
PPARγ-independent eﬀects of 15-deoxy-PGJ2 have been
also described. Jung et al. reported that this PPARγ ligand
was able to increase NGF-induced diﬀerentiation of PC-12
NB cells, as assessed by neurite extension and expression of
neuroﬁlament[65].PretreatmentwiththePPARγ antagonist
bisphenol A diglycidyl either did not alter the diﬀerentiating
activity of 15-deoxy-PGJ2. The fact that PC-12 cells do not
expressPPARγ furthersupportedthehypothesisthatthebio-
logical eﬀects elicited by 15-deoxy-PGJ2 were not mediated
by this receptor. Conversely, 15-deoxy-PGJ2 enhanced NGF-
induced p38 MAP kinase expression and phosphorylation as
well as the activation of transcription factor AP-1, that on
turn were counteracted by a speciﬁc inhibitor of p38 MAP
kinase (SB203580). Altogether, these data suggested that the
promoting eﬀect of 15-deoxy-PGJ2 on cell diﬀerentiation
may be mediated by the activation of p38 MAP kinase in
conjunction with the AP-1 signalling pathway.
Other studies addressed the role of synthetic PPARγ
ligands in counteracting cell growth in NB. In the already
mentioned work by Han et al., in which the presence of
PPARγ in NB cells was described for the ﬁrst time, the
authors also demonstrated that the synthetic PPARγ agonist
GW1929 induced the diﬀerentiation of LA-N-5 cells and
inhibited cell proliferation [54]. A subsequent study of the
same group showed that the prodiﬀerentiating eﬀect of
GW1929 is mediated by PPARγ, because it was inhibited
by the cotreatment with speciﬁc antagonists [66]. The
antiproliferativeeﬀectsoftheTZDsciglitazone,pioglitazone,
troglitazone, and rosiglitazone in diﬀerent NB cell lines
(i.e., LAN-1, LAN-5, LS, IMR-32, SK-N-SH, SH-SY5Y) wereAlessandro Peri et al. 3
determined by Valentiner et al. [67]. In these cell lines, which
expressPPARγ,thefourligandswereabletomarkedlyinhibit
cell growth at the highest doses that were used (10 and
100μM). Ciglitazone determined the strongest inhibitory
eﬀect (more than 90% inhibition). The potency of the
diﬀerent PPARγ ligands was not related to the amount of
expression of PPARγ in NB cell lines. Thus, the authors
hypothesized that the eﬀects of the molecules that were used
seem to be independent of the amount of PPARγ protein in
one particular cell line. Conversely, they concluded that the
response to PPARγ ligands may rather depend on various
cellular conditions, which are associated with the function
of the receptor, such as its activation, translocation to the
nucleusandbindingtoPPARresponseelements(PPRE).The
role played by PPARγ transactivation was conﬁrmed by the
ﬁndingthatgrowthinhibitiondeterminedby15-deoxy-PGJ2
and ciglitazone in NB cells was counteracted by the repres-
sion of PPARγ transactivation via retinoblastoma protein
overexpression[68].Furtherstudiesinvestigatedwhetherthe
inhibitory eﬀe c to fT Z D so nc e l lg r o w t hw a sm e d i a t e d ,a t
least partially, by a stimulatory eﬀect on apoptosis. Kato et
al. found that in NB-1 cells troglitazone induced PPARγ-
dependent apoptosis [69]. Similar data were reported later
on by Schultze et al. [70], who showed that in SHEP NB
cells the pro-apoptotic eﬀect of the death ligand TRAIL is
reinforced by troglitazone. However, troglitazone-induced
sensitization to TRAIL appeared to be PPARγ-independent,
because it was achieved at concentrations that failed to
activate PPARγ. Conversely, the authors highlighted the fact
that troglitazone may induce apoptotic death by various
PPARγ-independent mechanisms. In particular, troglitazone
led to a marked downregulation of the antiapoptotic protein
Survivin,aswellastoanupregulationoftheagonisticTRAIL
receptor TRAIL-R2.
Overall, these data strongly indicate that PPARγ ligands
a r ea b l et oe ﬀectively counteract cell growth and to induce
apoptosis in NB cells. Undoubtedly, the role of PPARγ in
eliciting these responses would be further clariﬁed by studies
designed for instance to manipulate gene expression (i.e., by
small interfering RNA or dominant negative strategies). To
our knowledge, there are only two reports from one Korean
group showing, in contrast to the current opinion, that a
PPARγ agonist (i.e., rosiglitazone) protects NB (SH-SY5Y)
cells against the neurotoxins acetaldehyde and 1-methyl-4-
phenylpyridinium ion, through inhibition of apoptosis [71,
72].
3. DIFFERENTIAL PPARγ TRANSACTIVATION IN
NEUROBLASTOMA CELL LINES WITH A DIFFERENT
PHENOTYPE: RELATIONSHIP WITH THE RESPONSE
TO ROSIGLITAZONE
NB is a phenotypically heterogeneous tumor, displaying cells
of neuronal, melanocytic, or glial/schwannian lineage. This
cellular heterogeneity is also present in vitro, where cells of
neuroblastic (N) or stromal (S) type may be identiﬁed. It
has been hypothesized that the sensitivity to PPARγ ligands
may be, at least partially, dependent on the diﬀerent cell
phenotype. To this purpose, Servidei et al. examined the
response of 8 diﬀerent NB cell lines with N (SH-SY5Y,
LA-N-5, SMS-KCNR, SK-N-DZ), mixed (SK-N-FI, LA-N-
1), or S (SH-EP1, SK-N-AS) phenotype to PPARγ agonists
[73]. All the cell lines investigated expressed a functionally
activePPARγ.15-deoxy-PGJ2 androsiglitazoneinhibitedcell
growth in all cell lines, and the sensitivity appeared to be
morerelatedtothecellphenotypethantoPPARγ expression.
In particular, the N type cells appeared the most sensitive
to treatment. In this experimental setting, the cotreatment
with PPARγ ligands and the RXR ligand 9-cis retinoic
acid did not determine any synergistic eﬀect on growth
inhibition. The more evident response of N type cells to
PPARγ ligandswasinpartrelatedtotheirhighercapabilityto
undergo apoptosis, although only 15-deoxy-PGJ2 appeared
toeﬀectivelyinducetheapoptoticcascadeinthesecells.Ithas
to be said that in this study some experimental observations
(i.e., apoptosis and cell viability) were not performed in all
the investigated NB cell lines.
Inordertofurtherclarifythemechanismsunderlyingthe
response of NB cells to PPARγ agonists, we compared the
response of two cell lines (SH-SY5Y, N type, and SK-N-AS,
S type) to rosiglitazone. In contrast to the above-mentioned
ﬁndings, we observed that micromolar concentrations of
rosiglitazone inhibited cell proliferation and reduced cell
viability more eﬀectively in SK-N-AS than in SH-SY5Y
[74]. The PPARγ antagonist BADGE reverted the eﬀect of
rosiglitazone, thus suggesting a direct role of PPARγ in
mediating the eﬀects of this agonist on cell proliferation
and viability. In addition, we found that SK-N-AS cells were
more sensitive to rosiglitazone in terms of reduction of cell
adhesion and invasiveness. The latter eﬀect was in agreement
with rosiglitazone-dependent reduced expression of matrix
metalloproteinase-9 (MMP-9). In addition, rosiglitazone
determined a trend toward increased expression levels of
tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
MMPs, which promote the invasion of extracellular matrix
by tumoral cells, have been related to the progression of
diﬀerent tumors, including NB [75, 76]. In our study, we
also addressed the possible role of rosiglitazone in inducing
apoptosis.Wedemonstratedthatmicromolarconcentrations
of this molecule were able to induce caspase-3 activation in
SK-N-AS, but not in SH-SY5Y (up to 50μM). Therefore,
all our data indicated that rosiglitazone played an eﬀective
antitumoral rolein theStypeSK-N-AS,yetnot in theNtype
SH-SY5Y NB cells. Although our study was limited to two
cell lines, this apparent prevalent eﬀect on a particular cell
phenotype may have clinical resonance. In fact, it is known
that in NB, following cytotoxic therapy, the residual tumor
often shows a reduction of the neuroblastic elements and the
persistence of stromal components [77]. Hence, a molecule
that appears to have S type NB cells as a preferential target
might be of interest in the setting of residual disease.
A further aim of our study was to determine the reason
underlying the peculiar sensitivity to rosiglitazone displayed
by SK-N-AS cells. Both SK-N-AS and SH-SY5Y expressed a
similaramountofPPARγ.However,intransienttransfection
experiments, in which a PPRE-thimidine kinase luciferase
reporter plasmid was inserted, we observed that in SK-N-AS
20μM rosiglitazone induced a near three-fold increase of the4 PPAR Research
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Figure 1: PPARγ transcriptional activity in control untreated
NB cells (C), in cells treated with rosiglitazone (RGZ) (20μM),
a n di nc e l l st r a n s f e c t e dw i t hP P A R γ and treated with RGZ.
L/C: peroxisome proliferator response element-n73-tk-luciferase
reporter activity, normalized for CAT activity. ∗ = P<0.05 versus
C. ∗∗ = P<0.05 versus C, and versus RGZ-treated cells, in the
absence of PPARγ transfection (from [74], modiﬁed).
reporter activity compared to untreated cells. Conversely, no
eﬀect was elicited in SH-SY5Y. Only when these cells were
co-transfected with a human PPARγ expression plasmid, the
response to rosiglitazone was present. These data indicated
that the original lack of response showed by SH-SY5Y was
due to a very low or absent transactivation potential of
the endogenous PPARγ (Figure 1). The diﬀerent eﬃcacy of
PPARγ as a transcriptional activator in the two cell lines
might be hypothetically due to the presence of a PPARγ
gene mutation. However, no mutation was found in the
entire coding region of the gene. Conversely, we found
that the amount of phosphorylated PPARγ was markedly
lower in SK-N-AS than in SH-SY5Y cells (Figure 2). There
is evidence that phosphorylation reduces the activity of
the receptor [78]. Therefore, our conclusion was that the
higher eﬃcacy of rosiglitazone in SK-N-AS cells was due
to a reduced phosphorylation status, hence to increased
activity, of PPARγ. To our knowledge, this was the ﬁrst
demonstration that the response of NB cells to TZDs may
be dependent on PPARγ transactivation.
4. PPARγ AGONISTS IN NEUROBLASTOMA
XENOGRAFT MODELS
To our knowledge, no study on the in vivo eﬀect of TZDs in
neuroblastoma has been published so far. However, our very
recent preliminary in vivo observations on CD-1 athymic
nude mice, in which SK-N-AS cells were subcutaneously
inoculated, appear to conﬁrm our previous in vitro observa-
tions [74]. Rosiglitazone (150mg/kg/day, in agreement with
the average dose used in other in vivo studies addressing
diﬀerent tumors) was administered by gavage for 4 weeks.
SK-N-AS SH-SY5Y
Anti-PPARγ
Anti-P-Ser
Figure 2: Detection of total (anti-PPARγ antibody) and phospho-
rylated (anti-P-Ser antibody) PPARγ, by Western blot analysis after
PPARγ immunoprecipitation (from [74], modiﬁed).
Tumoral growth was markedly reduced compared to control
mice, treated with the vehicle alone. At the end of treatment,
the weight of the tumor in rosiglitazone-treated animals
was about 60% less than in control animals [Cellai et al;
unpublished data]. An extensive molecular characterization
of tumor specimens is currently ongoing, in order to
elucidate the mechanisms underlying the growth inhibitory
eﬀect of rosiglitazone observed in vivo in our xenograft
model.
5. CONCLUSIONS
In the last few years in vitro studies have shown that PPARγ
agonists may inhibit NB cell growth by stimulating cell
diﬀerentiation and/or by inducing apoptosis. The diﬀerent
molecules that have been tested have generally produced
similar results. However, the mode of action may change
depending on the agonist and/or on the diﬀerent cell line
used. In addition, both PPARγ-dependent as well as PPARγ-
independent eﬀects have been described. Our recent data
suggest that PPARγ transactivation, determined at least in
part by the phosphorylation status of the receptor, may play
an important role in determining the response of NB cells to
PPARγ agonists. However, the exact mechanisms of action
and the possibility to predict the success or failure of the
treatmentofNBwiththesemoleculesare,atthistime,matter
of further in vitro as well as in vivo research.
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